1-8 of 8
John Kuruvilla
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Clinical Trials & Observations
Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Mariano Provencio, Ulrich Jäger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6266–6274.
https://doi.org/10.1182/bloodadvances.2023010334
Published: 2023
Includes: Supplemental data
Journal Articles

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Clinical Trials & Observations
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5272–5280.
https://doi.org/10.1182/bloodadvances.2023010254
Published: 2023
Includes: Supplemental data
Journal Articles

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martínez-López, Yucai Wang, Brian K. Link
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5835–5843.
https://doi.org/10.1182/bloodadvances.2022008150
Published: 2022
Journal Articles

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Jose S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Özcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla
Journal: Blood Advances
Blood Adv (2022) 6 (2): 590–599.
https://doi.org/10.1182/bloodadvances.2021004970
Published: 2022
Includes: Supplemental data
Journal Articles

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Clinical Trials & Observations
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, Christian Gisselbrecht
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4149–4155.
https://doi.org/10.1182/bloodadvances.2020003848
Published: 2021
Includes: Supplemental data
Journal Articles

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

Clinical Trials & Observations
Ho-Young Yhim, Yael Eshet, Ur Metser, Chae-Hong Lim, Katherine Lajkosz, Keren Isaev, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noémie Lang, Kyung-Han Lee, Wei Xu, David Hodgson, Richard Tsang, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim, Michael Crump, John Kuruvilla, Robert Kridel
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5762–5771.
https://doi.org/10.1182/bloodadvances.2020002814
Published: 2020
Includes: Supplemental data
Journal Articles

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

Christopher K. Rushton, Sarah E. Arthur, Miguel Alcaide, Matthew Cheung, Aixiang Jiang, Krysta M. Coyle, Kirstie L. S. Cleary, Nicole Thomas, Laura K. Hilton, Neil Michaud, Scott Daigle, Jordan Davidson, Kevin Bushell, Stephen Yu, Ryan N. Rys, Michael Jain, Lois Shepherd, Marco A. Marra, John Kuruvilla, Michael Crump, Koren Mann, Sarit Assouline, Joseph M. Connors, Christian Steidl, Mark S. Cragg, David W. Scott, Nathalie A. Johnson, Ryan D. Morin
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2886–2898.
https://doi.org/10.1182/bloodadvances.2020001696
Published: 2020
Includes: Supplemental data
Journal Articles

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

Clinical Trials & Observations
Philippe Armand, John Kuruvilla, Jean-Marie Michot, Vincent Ribrag, Pier Luigi Zinzani, Ying Zhu, Patricia Marinello, Akash Nahar, Craig H. Moskowitz
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2617–2622.
https://doi.org/10.1182/bloodadvances.2019001367
Published: 2020
Includes: Supplemental data